CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 223 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00870623
NCT00870623N/ACompleted

Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections

University of Nebraska·observational·Posted Mar 27, 2009·Updated Sep 15, 2023

In Brief

An observational study for Bloodstream Infection. Completed, enrolled 223 participants across 1 site.

Detailed Summary

Bloodstream infections (BSI) are a major cause of morbidity and mortality. Bloodstream infections are also costly and result in prolonged hospital stays. The duration of therapy necessary to clear blood stream infections is unknown and no study has systematically addressed this issue. However, the use of antimicrobials is not without consequence. These include financial cost, side-effects, promotion of superinfection (especially Clostridium difficile-associated diarrhea), and the promotion of microbial resistance. This study hypothesizes that a procalcitonin (host biomarker) and endotoxin (microorganism biomarker) guided treatment plan could significantly decrease unnecessary exposure to antibiotics in patients with bloodstream infections.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 27, 2009
Enrollment StartJun 1, 2009
Primary CompletionJan 13, 2016
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 17.3 years ago